Biogen Inc. (NasdaqGS:BIIB) has been working with Goldman Sachs (GS) to find potential buyout targets and has a shopping list from the bank of potential acquisitions, STAT's Damian Garde and Adam Feuerstein reported, citing a person familiar with the matter. Goldman provided Biogen with a list of smaller biotech companies that might fit with the company's focus on neuroscience, including Biohaven Pharmaceutical (BHVN), Aurinia Pharmaceuticals (AUPH) and Amylyx (AMLX) and "the company's risk-averse board, which has repeatedly rejected potential deals, could be increasingly receptive," the biotech reporters said.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
190.5 USD | -0.85% | -6.46% | -26.37% |
Apr. 17 | UBS Adjusts Biogen's Price Target to $214 From $250, Maintains Neutral Rating | MT |
Apr. 17 | Wedbush Cuts Biogen's Price Target to $213 From $245 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.37% | 27.69B | |
-6.10% | 84.46B | |
+3.95% | 40.85B | |
+52.09% | 24.28B | |
-6.59% | 17.09B | |
-32.37% | 13.67B | |
-10.45% | 11.79B | |
-15.88% | 11.86B | |
-2.85% | 8.07B | |
+0.53% | 7.51B |
- Stock Market
- Equities
- BIIB Stock
- News Biogen Inc.
- Biogen Reportedly Works with Goldman to Explore Possible Acquisitions